Skip to main content
    F

    Forte Biosciences Inc (FBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $76.99
    +0.00 (+0.00%)

    Market Cap: $1.63B

    Last updated: Aug 27, 2026 at 5:00 PM ET

    Forte Biosciences Inc (FBRX) Financials: Revenue, Profit and Cash Flow

    Updated Aug 11, 2026. Financial statements from company filings, amounts in US dollars.

    Forte Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$69.38M, operating cash flow was -$50.88M and free cash flow was -$51.00M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$23.33M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $70.66M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0-100.0%N/AN/AN/A
    Dec 2018$18.04M+43890.2%100.0%-254.2%-271.4%
    Dec 2017$41.00K-16.3%100.0%-91775.6%-94948.8%
    Dec 2016$49.00KN/A100.0%-64673.5%-68322.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$0$0$18.04M$41.00K$49.00K
    Gross profit$0$0$0$0$0$0$0$18.04M$41.00K$49.00K
    Research and development$58.25M$21.19M$21.86M$5.59M$13.85M$42.06M$2.68M$51.08M$29.11M$27.22M
    Operating income-$70.66M-$36.60M-$32.49M-$13.90M-$21.49M-$46.28M-$4.06M-$45.85M-$37.63M-$31.69M
    Net income-$69.38M-$35.48M-$31.48M-$13.88M-$21.71M-$46.49M-$4.07M-$48.95M-$38.93M-$33.48M
    EBITDAN/AN/AN/AN/AN/AN/A-$4.06M-$45.48M-$37.32M-$31.39M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$38.00K$0$0$0$6.00K$0
    Gross profit$0$0$45.00K$0$0$0-$10.00K$0$0$0-$6.00K$0
    Operating income-$24.60M-$22.44M-$24.57M-$18.38M-$11.58M-$16.12M-$7.35M-$8.63M-$12.82M-$7.80M-$6.38M-$10.22M
    Net income-$23.33M-$22.14M-$24.79M-$17.68M-$11.25M-$15.66M-$7.16M-$8.39M-$12.51M-$7.42M-$5.87M-$9.96M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $76.96M were 93.0% of total assets of $82.78M, against total liabilities of $21.79M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$82.78M$61.56M$38.98M$42.00M$43.31M$61.24M$7.66M$103.08M$92.07M$35.35M
    Current assets$80.59M$61.35M$38.33M$41.51M$42.52M$59.90M$7.51M$97.75M$90.63M$32.46M
    Cash and equivalents$76.96M$22.24M$37.13M$41.10M$42.04M$58.77M$6.94M$40.81M$35.93M$5.51M
    Total liabilities$21.79M$9.08M$3.67M$3.18M$1.76M$2.26M$1.91M$44.94M$20.99M$28.36M
    Short-term debtN/AN/AN/AN/AN/AN/A$4.74M$36.00K$7.20M$7.20M
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$26.20M$3.63M$13.64M
    Shareholder equity$60.99M$52.48M$35.31M$38.82M$41.55M$58.98M-$4.77M$58.15M$71.08M-$124.42M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$205.74M$67.22M$82.78M$97.09M$107.78M$47.46M$61.56M$17.95M$26.08M$32.02M$38.98M$47.88M
    Total liabilities$21.95M$25.12M$21.79M$12.99M$9.17M$9.03M$9.08M$8.58M$9.12M$3.33M$3.67M$7.47M
    Cash and equivalents$49.63M$58.22M$76.96M$93.41M$106.14M$45.86M$22.24M$16.36M$24.50M$30.44M$11.96M$46.19M
    Shareholder equity$183.79M$42.10M$60.99M$84.10M$98.61M$38.43M$52.48M$9.37M$16.96M$28.68M$35.31M$40.41M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$50.88M-$30.75M-$28.71M-$8.19M-$16.68M-$18.42M-$2.77M-$34.47M-$31.13M-$29.54M
    Capital expenditures$116.00K$37.00K$88.00K$0$61.00K$0$162.00K$1.97M$655.00K$525.00K
    Free cash flow-$51.00M-$30.78M-$28.79M-$8.19M-$16.74M-$18.42M-$2.93M-$36.44M-$31.79M-$30.06M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/A$16.00KN/A$592.00K
    Investing cash flow$36.23M-$35.99M$47.00K$0$0$3.58M-$162.00K-$4.19M-$27.71M$24.57M
    Financing cash flow$69.36M$51.86M$24.68M$7.24M-$44.00K$66.67M$4.86M$43.54M$89.26M$2.33M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$22.70M-$18.81M-$16.47M-$14.00M-$10.06M-$10.36M-$10.01M-$8.13M-$5.94M-$6.67M-$8.97M-$9.06M
    Capital expendituresN/A$0$0$55.00K$0$61.00K$31.00K$0$0$6.00K$17.00K$71.00K
    Free cash flowN/A-$18.81M-$16.47M-$14.05M-$10.06M-$10.42M-$10.04M-$8.13M-$5.94M-$6.67M-$8.99M-$9.13M
    Last 12 quarters

    Frequently Asked Questions About FBRX

    What is Forte Biosciences' annual revenue?

    Forte Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Forte Biosciences profitable?

    No. Forte Biosciences reported net income of -$69.38M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does FBRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$50.88M minus capital expenditures of $116.00K produced free cash flow of -$51.00M.

    How much debt does Forte Biosciences have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $76.96M.